Back to top
more

Puma Biotechnology (PBYI)

(Real Time Quote from BATS)

$4.23 USD

4.23
71,643

-0.14 (-3.20%)

Updated May 21, 2024 10:50 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (88 out of 248)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why You Should Add Xenon (XENE) to Your Portfolio Now

by Zacks Equity Research

Xenon's (XENE) late-stage studies in epilepsy are progressing well. The company is also gearing up to initiate a late-stage study for the MDD indication in 2024.

Alvotech (ALVO) Up on BLA Update for Two Biosimilar Candidates

by Zacks Equity Research

The FDA concludes the reinspection of Alvotech's (ALVO) facility in Iceland. The company believes that it may receive approval for biosimilar candidates, AVT02 and AVT04, in the United States. Stock rises.

Should You Add Marinus (MRNS) Stock to Your Portfolio Now?

by Zacks Equity Research

Here, we discuss some reasons why investing in Marinus Pharmaceuticals' (MRNS) stock may turn out to be a prudent move.

Puma Biotech (PBYI) Is Attractively Priced Despite Fast-paced Momentum

by Zacks Equity Research

Puma Biotech (PBYI) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.

Verastem (VSTM) Up 8% on Fast Track Tag for NSCLC Combo Therapy

by Zacks Equity Research

Verastem's (VSTM) avutometinib/Lumakras combination therapy gets the FDA's Fast Track designation to treat KRAS G12C-mutant metastatic NSCLC patients. The stock gains 8% in response.

Mesoblast (MESO) Up on Rare Pediatric Disease Tag for Heart Drug

by Zacks Equity Research

Mesoblast's (MESO) Revascor (rexlemestrocel-L) gets FDA's Rare Pediatric Disease designation for treating children with congenital heart disease. Shares rise in after-hours trading.

Exelixis (EXEL) Reports Positive EU Patent Ruling for Cabometyx

by Zacks Equity Research

Exelixis (EXEL) gets a favorable ruling from the European Patent Office in a lawsuit related to its oral oncology drug, Cabometyx.

Syros (SYRS) Stock Surges 200% in 3 Months: Here's Why

by Zacks Equity Research

Syros (SYRS) is progressing well with the development of its pipeline candidate, tamibarotene, targeting two different cancer indications.

Vor Bio (VOR) Up on Positive Update From AML Cell Therapy Study

by Zacks Equity Research

Vor Bio (VOR) stock gains after dosing the first patient in its phase I/II study of novel cell therapy, VCAR33 (Allogenic), to treat AML. The company extends its cash runway into the second half of 2025.

Instil (TIL) Stock Rises More Than 20% in a Week: Here's Why

by Zacks Equity Research

Instil's (TIL) recent deal with a collaborator to carry out preclinical manufacturing feasibility studies on its ITIL-306 program is a positive.

Is it a Good Idea to Invest in Intellia (NTLA) Stock Now?

by Zacks Equity Research

Here, we discuss some reasons why investing in Intellia (NTLA) stock now may turn out to be a more prudent move than ever.

Here's Why You Should Invest in Avadel (AVDL) Stock Now

by Zacks Equity Research

Here, we discuss some reasons why buying Avadel Pharmaceuticals (AVDL) stock now may turn out to be a prudent move.

Sana Bio (SANA) Stock Rallies 105% in 3 Months: Here's Why

by Zacks Equity Research

Sana Bio (SANA) rallies 105% after the company reports encouraging pipeline progress with its candidates, SC291 and SC262, for oncology and autoimmune indications.

Solid Biosciences' (SLDB) DMD Drug Gets Orphan Tag, Stock Up

by Zacks Equity Research

Solid Biosciences (SLDB) stock rises after the FDA grants the orphan drug designation to the company's novel gene-therapy candidate, SGT-003, for the treatment of Duchenne muscular dystrophy.

Regeneron (REGN), Sanofi's Dupixent Gets Label Update in US

by Zacks Equity Research

The FDA updates Regeneron (REGN) and Sanofi's Dupixent label in the United States to include efficacy and safety data for patients aged 12 years and older with atopic dermatitis with uncontrolled moderate-to-severe hand and/or foot involvement.

Aclaris (ACRS) Stock Rises on Appointment of New Interim CEO

by Zacks Equity Research

Aclaris (ACRS) appoints Neal Walker as interim CEO after current CEO, Douglas Manion, steps down from his role. Shares rise.

Annexon (ANNX) Stock Rallies 156% in 3 Months: Here's How

by Zacks Equity Research

Annexon (ANNX) has rallied 156% in the past three months on plans to begin a registrational program for ANX007 in GA after reaching FDA alignment on the study's primary endpoint.

Puma Biotech (PBYI) Stock Jumps 10.0%: Will It Continue to Soar?

by Zacks Equity Research

Puma Biotech (PBYI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Reasons to Add Blueprint (BPMC) Stock to Your Portfolio Now

by Zacks Equity Research

Here, we discuss some reasons why investing in Blueprint (BPMC) stock now may turn out to be a more prudent move than ever.

IGM Bio (IGMS) Stock Rallies 142% in 3 Months: Here's Why

by Zacks Equity Research

IGM Bio (IGMS) stock surges 142% in the past three months on strategic reprioritization efforts to focus its resources on the development of pipeline candidates for cancer and autoimmune indications.

Adicet (ACET) Stock Rallies 130% in a Month: Here's Why

by Zacks Equity Research

Adicet (ACET) skyrockets 130% on a corporate update provided by the company discussing strategic priorities for 2024.

Solid Biosciences (SLDB) Rises 271% in 3 Months: Here's Why

by Zacks Equity Research

The FDA's recent clearance of Solid Biosciences' (SLDB) investigational new drug application on SGT-003 for treating Duchenne muscular dystrophy pushes the stock higher.

Inovio Pharma (INO) Stock Rallies 134% in a Month: Here's Why

by Zacks Equity Research

Inovio Pharma (INO) surges 134% in a month, mainly due to its plans to submit a regulatory application seeking approval of its lead candidate, INO-3107, in the second half of 2024 to treat RRP.

Amicus (FOLD) Stock Rises More Than 25% in 3 Months: Here's Why

by Zacks Equity Research

Sales of Amicus' (FOLD) lead drug, Galafold, are rising consistently. Also, the recent approval of the Pompe disease drug combination, Pombiliti + Opfolda, is a positive.

Amarin (AMRN) Stock Rises on Stellar Q4 Preliminary Results

by Zacks Equity Research

Amarin (AMRN) issues encouraging preliminary results for the fourth quarter and full-year 2023. The company also plans to initiate a share repurchase program of up to $50 million. Stock gains.